Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies (Tables)

v3.25.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies  
Schedule of significant expense categories

​

​

​

​

​

​

​

​

​

    

Year Ended

​

​

December 31,

​

December 31,

​

    

2024

​

2023

Operating expenses:

​

​

​

​

​

​

Clinical

​

$

1,153,345

​

$

112,196

Chemical, manufacturing and controls

​

​

710,055

​

​

312,691

Research and preclinical

​

​

505,750

​

​

267,803

Regulatory

​

​

20,065

​

​

186,395

Other research and development costs

​

​

1,141,698

​

​

848,993

Total research and development

​

​

3,530,913

​

​

1,728,078

General and administrative expenses

​

​

8,696,335

​

​

3,718,841

Total operating expenses

​

$

12,227,248

​

$

5,446,919

Interest expense (income), net

​

​

92,192

​

​

(150,904)

Exchange loss, net

​

 

30,787

​

 

—

Net loss before income taxes

​

$

12,350,227

​

$

5,296,015